Evidence map›Paper›PMID 40754541›Full record

ArticleScientific reports2025

A multinational cross-sectional study on the prevalence and predictors of long COVID across 33 countries.

Mohamed Sayed Zaazouee, Eman Ayman Nada, Mohammed Al-Kafarna, Ahmed Shaheen, Shivabalan Kathavarayan Ramu, Abdelrahman H Hafez, Sajeda Ghassan Matar, Ahmed Assar, Mohamed Elshennawy, Hazem Abu El-Enien and 16 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Understanding the Impact of Long COVID on the Lives of Thai University Students.International journal of environmental research and public health · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Mohamed Sayed ZaazoueeFaculty of Medicine, Al-Azhar University, Assiut, Egypt. MohamedZaazouee.stu.6.44@azhar.edu.eg.
Eman Ayman NadaFaculty of Pharmacy, Tanta University, Tanta, Gharbia, Egypt.
Mohammed Al-KafarnaSchool of Public Health, Al-Quds University - Abu Dees, Jerusalem, Palestine.
Ahmed ShaheenFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Shivabalan Kathavarayan RamuHeart, Vascular, and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Abdelrahman H HafezFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Sajeda Ghassan MatarFaculty of Pharmacy, Applied Science Private University, Amman, Jordan.
Ahmed AssarFaculty of Medicine, Menofia University, Shibin El Kom, Menofia, Egypt.
Mohamed ElshennawyFaculty of Medicine, Al-Azhar University, Assiut, Egypt.
Hazem Abu El-EnienPureHealth, Abu Dhabi, United Arab Emirates.
Hala Jamal RedwanFaculty of Pharmacy, Al-Azhar University, Gaza, Palestine.
Sarah Makram ElsayedFaculty of Medicine, October 6 University, Giza, Egypt.
Maha Jabir OmranSorbonne Université, Faculté de Médecine, Paris, France.
Omar Hammam SalloumFaculty of Medicine, Palestine Polytechnic University, Hebron, Palestine.
Hossam AlmadhoonInstitute of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, Glasgow, UK.
Mohamed MamdouhFaculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Engy A WahshFaculty of Pharmacy, October 6 University, Giza, Egypt.
Anas Zakarya NoureldenFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Alaa Ahmed ElshanbaryFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Walid Abdel-AzizFaculty of Medicine, Al-Azhar University, Assiut, Egypt.
Hivan Haji RashidFaculty of Medicine, Aleppo University, Aleppo, Syria.
Iman BashetiPharmaceutical Sciences Department, Faculty of Pharmacy, Jadara University, Irbid, Jordan.
Khaled Mohamed RagabFaculty of Medicine, Minia University, Minya, Egypt.
Ahmed Taher MasoudFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Abdelrahman I AbushoukDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Long-COVID International Team (LCIT)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The symptoms of long COVID (LC) can be debilitating and may be associated with anxiety, social stigma, and quality of life deterioration. Identifying patients at risk of LC is important to offer follow-up care and plan population-level public health measures. The current multinational study aimed to assess the prevalence and predictors of LC in the general population. We conducted an online, multinational, cross-sectional survey between April 2022 and January 2023, targeting participants 18 years and older with a previously confirmed COVID-19 infection. We used convenience sampling to recruit participants through an online Google form. We collected demographic data, past medical history, infection details, post-COVID-19 symptoms, and quality of life. Responses were then translated into English. LC was defined as per the World Health Organization. A single-variable analysis was conducted to identify factors significantly associated with LC development. Following the removal of multicollinear variables, a generalized linear model was established to estimate the contribution of different predictors to LC occurrence. A total of 11,801 respondents from 33 countries were included in the analysis. The mean age for participants was 32.7 ± 12.8 years, with 61% being females. BMI averaged 25.2 ± 4.8 across participants, and 14.8% of them were smokers. Seventy-eight percent of participants reported receiving the COVID-19 vaccine. Respondents with PCR-confirmed COVID-19 were then categorized into those with LC (N = 2335, 19.8%) and without LC (N = 9466 individuals, 80.2%). Our model identified 25 significant predictors. The predictors of higher LC risk included ICU admission (OR 2.08; 95% CI 1.36, 3.18; P = 0.001), female sex (OR 1.8; 95% CI 1.61, 2.02; P < 0.001), fatigue during the infection (OR 1.6; 95% CI 1.43, 1.78; P < 0.001), identifying as Hispanic (OR 1.53; 95% CI 1.26, 1.85; P < 0.001), and pre-existing gastrointestinal disease (OR 1.48; 95% CI 1.22, 1.8; P < 0.001). In conclusion, we identified key LC predictors, including ICU admission, female sex, and acute fatigue as primary risk factors, while African American and Asian ethnicities and receiving even one dose of vaccination demonstrated protective effects.

Indexed as

COVID-19AdolescentAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrevalenceQuality of LifeRisk FactorsSARS-CoV-2Young AdultCovid-19Long CovidMulti-nationalRe-infectionVaccination

Identifiers

PMID40754541
PMCPMC12319108

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.